Böbrek Kanserinde Radyofrekans Ablasyon
Özet
Böbrek tümörleri, erişkin kanserlerinin %3-5’ini oluşturmakta ve dünya genelinde görülme sıklığı giderek artmaktadır. Görüntüleme yöntemlerinin yaygınlaşmasıyla erken evrede (T1) yakalanan kitlelerin tedavisinde, kronik böbrek yetmezliği riskini azaltan nefron koruyucu cerrahiler (parsiyel nefrektomi) ön plana çıkmıştır. Ancak hastaların mevcut ek hastalıkları ve cerrahi riskleri, radyofrekans ablasyon (RFA) gibi minimal invazif yöntemlerin doğmasını sağlamıştır. RFA, hedef dokuda yüksek ısı veya empedans oluşturarak tümör hücrelerini yok etmeyi amaçlayan bir teknolojidir. Genellikle çapı 3 cm’den küçük kitlelerde parsiyel nefrektomiye alternatif olarak güvenle uygulanan bu yöntem, perkütan veya laparoskopik yollarla gerçekleştirilebilir. Yapılan uzun dönemli onkolojik çalışmalar, 3 cm’den küçük kitlelerde RFA başarısının %97’lere ulaştığını ve 10 yıllık kansere özgü sağkalım oranlarının son derece yüksek olduğunu göstermektedir. Ameliyat süresi, hastanede kalış günü ve maliyet açısından cerrahi yöntemlere göre belirgin avantajlar sunan RFA, majör komplikasyon oranlarının düşüklüğü ile de dikkat çekmektedir. Sonuç olarak RFA, özellikle ileri yaşta, cerrahiye uygun olmayan veya operasyonu reddeden seçilmiş hasta gruplarında etkinliği kanıtlanmış, nefron koruyucu ve düşük maliyetli başarılı bir tedavi seçeneğidir.
Renal tumors account for 3-5% of adult cancers, with a globally increasing incidence rate. With the widespread use of radiological imaging, these tumors are detected at earlier stages (T1), leading nephron-sparing surgery (partial nephrectomy) to replace radical approaches to prevent chronic kidney disease. However, patient comorbidities and potential surgical complications have driven the development of minimally invasive techniques such as radiofrequency ablation (RFA). RFA utilizes alternating electrical currents to generate high thermal energy or impedance, causing optimal cellular death in target tissues. Performed via either percutaneous or laparoscopic routes, this technique serves as an alternative to surgery, particularly for masses smaller than 3 cm. Long-term oncological data indicate that RFA achieves a success rate of up to 97% for tumors under 3 cm, demonstrating high cancer-specific survival rates over 10-year follow-ups. Compared to partial nephrectomy, RFA offers comparable complication rates while significantly reducing operation time, hospital stays, and overall medical costs. Consequently, RFA stands out as an effective, safe, and cost-efficient nephron-sparing modality for select patient populations, including the elderly and those unsuitable for or unwilling to undergo standard surgery.
Referanslar
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71: 7-33.
Huang J, Leung DK, Chan EO, Lok V, Leung S, Wong I, Lao XQ, Zheng ZJ, Chiu PK, Ng CF, Wong JH, Volpe A, Merseburger AS, Powles T, Teoh JY, Wong MCS. A global trend Aanalysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome. Eur Urol Focus. 2021 doi: 10.1016/j.euf.2020.12.020. (Basımda)
Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387: 894-906.
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG; Practice guidelines committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182: 1271-9.
Seveso M, Grizzi F, Bozzini G, Mandressi A, Guazzoni G, Taverna G. Open partial nephrectomy: ancient art or currently available technique? Int Urol Nephrol. 2015;47: 1923-32.
Massarweh NN, Cosgriff N, Slakey DP. Electrosurgery:history, principles, and current and future uses. J Am Coll Surg. 2006; 220: 520-530.
Zlotta AR, Wildschutz T, Raviv G, Peny MO, van Gansbeke D, Noel JC, Schulman CC. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol. 1997;11: 251-258.
Salagierski M, Wojciechowska A, Zając K, Klatte T, Thompson RH, Cadeddu JA, Kaouk J, Autorino R, Ahrar K, Capitanio U. Young academic urologists kidney cancer working group of the European Urological Association. The role of ablation and minimally invasive techniques in the management of small renal masses. Eur Urol Oncol. 2018;1: 395-402.
Ginzburg S, Tomaszewski JJ, Kutikov A. Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nat Rev Urol. 2017;14: 669-82.
Shi X, Pan H, Ge H, Li L, Xu Y, Wang C, Xie H, Liu X, Zhou W, Wang S. Subsequent cooling-circulation after radiofrequency and microwave ablation avoids secondary indirect damage induced by residual thermal energy. Diagn Interv Radiol. 2019; 25: 291-7.
Kimura M, Baba S, Polascik TJ. Minimally invasive surgery using ablative modalities for the localized renal mass. Int J Urol. 2010;17: 215-27.
Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy:a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000;174: 323-31.
Tracy CR, Cadeddu JA. Nonsurgical focal therapy for renal tumors, radiofrequency ablation. Campbell-Walsh-Wein Urology, 12th edition, Partin AW, Dmochowski RR, Kavoussi RL, Peters CA. Philadelphia,2021; 10660-10695.
Cha DI, Lee MW, Jeong WK, Ha SY, Ahn SH, Rhim H, Lim HK. Comparison of ablation performance between dual internally cooled wet tip and conventional dual internally cooled tip radiofrequency electrodes:an experimental study in ex vivo bovine liver. Int J Hyperthermia. 2021;38: 332-40.
Ljungberg B, Albiges L, Bedke J, Bex A, Capitanio U, Giles RH, Hora M, Klatte T, Lam T, Marconi L, Powles T, Volpe A. Renal cell carcinoma. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. EAU Guidelines Office, Arnhem, 2021; 1-84.
Lam CJ, Wong NC, Voss M, Mironov O, Connolly M, Matsumoto ED, Kapoor A. Surveillance post-radiofrequency ablation for small renal masses:recurrence and followup. Can Urol Assoc J. 2020;14: 398-403.
Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM. Renal mass and localized renal cancer: AUA Guideline. J Urol. 2017;198: 520-29.
Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Management of small renal masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20;35: 668-80.
National Comprehensive Cancer Network. Kidney Cancer (Version 4.2021). https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf Accessed April 22, 2021.
Castle SM, Gorbatiy V, Ekwenna O, Leveillee RJ. Laparoscopic and image-guided radiofrequency ablation of renal tumors: patient selection and outcomes. Curr Urol Rep. 2011;12: 100-6.
21.Vricella GJ, Ponsky LE, Cadeddu JA. Ablative technologies for urologic cancers. Urol Clin North Am. 2009;36: 163-78.
Matsumoto ED, Johnson DB, Ogan K, Trimmer C, Sagalowsky A, Margulis V, Cadeddu JA. Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors. Urology. 2005;65: 877-81.
Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Boorjian SA, Carter RE, Geske JR, Callstrom MR, Atwell TD. Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. J Urol. 2013;189: 30-5.
Schmit GD, Kurup AN, Weisbrod AJ, Thompson RH, Boorjian SA, Wass CT, Callstrom MR, Atwell TD. ABLATE:a renal ablation planning algorithm. AJR Am J Roentgenol. 2014;202: 894-903.
Kim KR, Thomas S. Complications of image-guided thermal ablation of liver and kidney neoplasms. Semin Intervent Radiol. 2014;31: 138-48.
Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Callstrom MR, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2019;76: 244-251.
Lum MA, Shah SB, Durack JC, Nikolovski I. Imaging of small renal masses before and after thermal ablation. Radiographics. 2019;39: 2134-45.
Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Long- term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 2013;63: 486–92.
Johnson BA, Sorokin I, Cadeddu JA. Ten-year out-comes of renal tumor radio frequency ablation. J Urol 2019;201: 251–258.
Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA. Durable oncologic outcomes after radiofrequency ablation. Cancer 2010;116: 3135-3142.
Ma Y-B, Bedir S, Cadeddu JA, Gahan JC. Long-term outcomes in healthy adults after radiofrequency ablation of T1a tumours. BJU Int 2013;113: 51-55.
Pan XW, Cui XM, Huang H, Huang Y, Li L, Wang ZJ, Qu FJ, Gao Y, Cui XG, Xu DF. Radiofrequency ablation versus partial nephrectomy for treatment of renal masses: A systematic review and meta-analysis. Kaohsiung J Med Sci. 2015;31: 649-658.
Yin X, Cui L, Li F, Qi S, Yin Z, Gao J. Radiofrequency ablation versus partial nephrectomy in treating small renal tumors:a systematic review and meta-analysis. Medicine (Baltimore). 2015;94: e2255.
Rivero JV, De La Cerda J 3rd, Wang H, Liss MA, Farrell AM, Rodriguez R, Suri R, Kaushik D. Partial nephrectomy versus thermal ablation for clinical stage T1 renal masses:systematic review and meta-analysis of more than 3900 patients. J Vasc Interv Radiol. 2018; 29:18-29.
Uhlig J, Strauss A, Rücker G, Seif Amir Hosseini A, Lotz J, Trojan L, Kim HS, Uhlig A. Partial nephrectomy versus ablative techniques for small renal masses:a systematic review and netwoek meta-analysis. Eur Radiol. 2019; 29:1293-1307.
Bensalah K, Zeltser I, Tuncel A, Cadeddu J, Lotan Y. Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours. BJU Int. 2008;101: 467-471.
Vollherbst D, Bertheau R, Kauczor HU, Radeleff BA, Pereira PL, Sommer CM. Treatment failure after image-guided percutaneous radiofrequency ablation (RFA) of renal tumors-a systematic review with description of type, frequency, risk factors and management. Rofo. 2017;189: 219-27.
Castle SM, Gorbatiy V, Avallone MA, Eldefrawy A, Caulton DE, Leveillee RJ. Cost comparison of nephron-sparing treatments for cT1a renal masses. Urol Oncol. 2013;31: 1327e32.
Lotan Y, Cadeddu JA. A cost comparison of nephron-sparing surgical techniques for renal tumour. BJU Int. 2005;95: 1039e42.
